STSA
Price:
$1.1
Market Cap:
$36.47M
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2019-09-13
Stock Exchange
NASDAQ
Ticker
STSA
According to Satsuma Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.55. This represents a change of -64.09% compared to the average of -1.54 of the last 4 quarters.
The mean historical PE Ratio of Satsuma Pharmaceuticals, Inc. over the last ten years is -6.67. The current -0.55 PE Ratio has changed 729.05% with respect to the historical average. Over the past ten years (40 quarters), STSA's PE Ratio was at its highest in in the December 2022 quarter at -0.33. The PE Ratio was at its lowest in in the September 2018 quarter at -18.11.
Average
-6.67
Median
-3.30
Minimum
-22.23
Maximum
-0.42
Discovering the peaks and valleys of Satsuma Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 52.16%
Maximum Annual PE Ratio = -0.42
Minimum Annual Increase = -83.73%
Minimum Annual PE Ratio = -22.23
Year | PE Ratio | Change |
---|---|---|
2022 | -0.42 | -83.73% |
2021 | -2.56 | 52.16% |
2020 | -1.68 | -58.41% |
2019 | -4.05 | -55.38% |
2018 | -9.07 | -59.19% |
The current PE Ratio of Satsuma Pharmaceuticals, Inc. (STSA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.55
5-year avg
-3.56
10-year avg
-6.67
Satsuma Pharmaceuticals, Inc.’s PE Ratio is greater than ZIVO Bioscience, Inc. (-2.46), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Erasca, Inc. (-3.94), less than Forte Biosciences, Inc. (-0.39), less than Applied Molecular Transport Inc. (-0.14), greater than SAB Biotherapeutics, Inc. (-0.65), less than Senti Biosciences, Inc. (-0.23), greater than Cingulate Inc. (-1.82), less than Bellicum Pharmaceuticals, Inc. (-0.11), less than Hillstream BioPharma, Inc. (-0.00), greater than Kronos Bio, Inc. (-0.58), less than Cyclerion Therapeutics, Inc. (2.44), greater than Larimar Therapeutics, Inc. (-8.80), greater than Addex Therapeutics Ltd (-81.79), less than Achilles Therapeutics plc (-0.45), greater than Assembly Biosciences, Inc. (-2.10), less than CytomX Therapeutics, Inc. (9.19), greater than Instil Bio, Inc. (-0.78), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than PMV Pharmaceuticals, Inc. (-1.58), greater than Eliem Therapeutics, Inc. (-3.49), greater than MediciNova, Inc. (-12.61), greater than Pharvaris N.V. (-8.20), greater than PepGen Inc. (-3.22),
Company | PE Ratio | Market cap |
---|---|---|
-2.46 | $37.03M | |
-3.19 | $181.50M | |
-3.94 | $807.96M | |
-0.39 | $11.11M | |
-0.14 | $11.01M | |
-0.65 | $26.03M | |
-0.23 | $13.14M | |
-1.82 | $12.90M | |
-0.11 | $778.33K | |
-0.00 | $4.17M | |
-0.58 | $59.36M | |
2.44 | $7.94M | |
-8.80 | $513.64M | |
-81.79 | $17.80M | |
-0.45 | $29.58M | |
-2.10 | $107.81M | |
9.19 | $93.74M | |
-0.78 | $92.68M | |
-0.98 | $8.20M | |
-1.58 | $77.28M | |
-3.49 | $495.57M | |
-12.61 | $103.00M | |
-8.20 | $1.03B | |
-3.22 | $287.77M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Satsuma Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Satsuma Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Satsuma Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the highest PE Ratio for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the 3-year average PE Ratio for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the 5-year average PE Ratio for Satsuma Pharmaceuticals, Inc. (STSA)?
How does the current PE Ratio for Satsuma Pharmaceuticals, Inc. (STSA) compare to its historical average?